Literature DB >> 8781718

Toxic epidermal necrolysis in a burns centre: a 6-year review.

A K Khoo1, C L Foo.   

Abstract

Toxic epidermal necrolysis (TEN) is the most severe of the Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TEN) spectrum. It is characterized by epidermal exfoliation and mucositis and carries an average mortality of 25 per cent. In this 6-year retrospective study, we reviewed 23 patients with drug-induced SJS-TEN. The most common causative agents were anticonvulsants and traditional medication. The mean time of onset of symptoms was 4.1 days (range 1-16 days) and the mean body surface area involved was 57.2 per cent (range 30-90 per cent). The condition was most commonly associated with ocular complications and sepsis. Using our treatment protocol in a burns centre, we were able to achieve a mean time to complete healing of 20.2 days (range 7-53 days) and a mean duration of hospitalization of 34.1 days (range 7-134 days). The length of hospital stay was prolonged when non-ocular complications supervened. The percentage mortality in our series was 10 per cent. It is our contention that the best results are obtained with treatment of the SJS-TEN patient in a burns centre with an internist, dermatologist and infectious disease specialist as part of the management team.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781718     DOI: 10.1016/0305-4179(95)00140-9

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  9 in total

1. 

Authors:  A Mokline; I Rahmani; L Garsallah; S Tlaili; R Hammouda; A A Messadi
Journal:  Ann Burns Fire Disasters       Date:  2016-03-31

2.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

3.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

Authors:  P Brent Ferrell; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

4.  Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients.

Authors:  Hye-In Kim; Shin-Woo Kim; Ga-Young Park; Eu-Gene Kwon; Hyo-Hoon Kim; Ju-Young Jeong; Hyun-Ha Chang; Jong-Myung Lee; Neung-Su Kim
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

5.  Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma.

Authors:  Mun Ki Choi; Hyun Young Woo; Jeong Heo; Mong Cho; Gwang Ha Kim; Geun Am Song; Moon Bum Kim
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

6.  Lyell's Syndrome and Antimalarials: A Case Report and Clinical Review.

Authors:  Joana Miranda Nunes; Sofia Santareno; Lina Guerreiro; Ana Filipa Margalho
Journal:  J Glob Infect Dis       Date:  2017 Jan-Mar

Review 7.  Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2013-10-31

8.  Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!

Authors:  Rajesh Kumar; Anupam Das; Sudip Das
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

Review 9.  Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.

Authors:  Izumi Sato; Hiroki Mizuno; Nobutaka Kataoka; Yusuke Kunimatsu; Yusuke Tachibana; Takumi Sugimoto; Nozomi Tani; Yuri Ogura; Kazuki Hirose; Takayuki Takeda
Journal:  Medicina (Kaunas)       Date:  2020-08-11       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.